Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group
Rüdiger Hehlmann(Heidelberg University), A. Georgii(University of Mannheim), Joerg Hasford(Ludwig-Maximilians-Universität München), H. Löffler(University of Mannheim), DK Hossfeld(University of Mannheim), HJ Kolb(University of Mannheim), B Heinze(University of Mannheim), H. Pralle(University of Mannheim), W. Queißer(University of Mannheim), H. Heimpel(University of Mannheim)
Cited by 207
Related Papers
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573